United Therapeutics Corp UTHR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
-
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
-
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
-
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
-
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
-
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
-
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
-
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $571.38
- Day Range
- $541.27–577.02
- 52-Week Range
- $409.07–609.35
- Bid/Ask
- $535.00 / $541.70
- Shares Outstanding
- 42.89M
- Market Cap
- $23.23B
- Volume/Avg
- 1M / 613,135
Key Statistics
- Price/Earnings (Normalized)
- 18.69
- Price/Sales
- 8.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 10.43%
Company Profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,400
- Website
- https://www.unither.com
Valuation
|
Metric
|
UTHR
|
|---|---|
Price/Earnings (Normalized) | 18.69 |
Price/Book Value | 3.81 |
Price/Sales | 8.50 |
Price/Cash Flow | 15.07 |
Price/Earnings
UTHR
Financial Strength
|
Metric
|
UTHR
|
|---|---|
Quick Ratio | 4.89 |
Current Ratio | 5.73 |
Interest Coverage | 118.51 |
Quick Ratio
UTHR
Profitability
|
Metric
|
UTHR
|
|---|---|
Return on Assets (Normalized) | 19.44% |
Return on Equity (Normalized) | 21.74% |
Return on Invested Capital (Normalized) | 19.84% |
Return on Assets
UTHR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|GbsxnlM% | LOCK|$%JR< | $66B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|?%#f&hv | LOCK|?#<@ | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|G?f#V@# | LOCK|NW@ | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|?#%<<J$s | LOCK|Bw | $29B | |||
| Viatris Inc
VTRS
| LOCK|Xy<HssC | LOCK|TX | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|#< | LOCK|f%K | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|!VQwdC | LOCK|Nm | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|tZl!prl | LOCK|LD | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|M^#L>!r | LOCK|p%rD | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|?>BQt!! | LOCK|&V | $2B |
United States